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Summary
Objective: Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) reﬂects cartilage glycosaminoglycan (GAG) distribution. The technique
assumes that the plasma levels of the contrast agent Gd-DTPA2 are the same across individuals after intravenous (IV) injection, when dosing
by weight. However, adipose tissue has lower extracellular water (ECW) than lean tissue. The aims of this study were to measure (1) plasma
Gd-DTPA2 levels vs body mass index (BMI), and (2) dGEMRIC vs BMI after correcting for the doseeBMI effect.
Method: (1) Plasma Gd-DTPA2 levels were analyzed at 3e90 min after IV injection per body weight in 24 individuals with BMI between 21.5
and 46.5. (2) dGEMRIC was compared with BMI in 19 asymptomatic volunteers and 23 with osteoarthritis (OA).
Results: (1) Plasma Gd-DTPA2 kinetics were similar in obese and non-obese groups, however, overall concentration was higher in the obese
group. A very obese subject (BMI 45) would have 1.4 times higher Gd-DTPA2 concentration than a lean subject (BMI 20), which translates
into a bias in dGEMRIC of up to 20%. (2) With dose bias taken into account, dGEMRIC showed no correlation with BMI in asymptomatic
knees. In OA knees, unnarrowed femoral compartments demonstrated a negative correlation between dGEMRIC and BMI (R¼ 0.57,
P¼ 0.004). No correlation was seen in radiographically narrowed compartments.
Conclusion: BMI can be a source of dosing bias in dGEMRIC and a correction factor should be considered in cross-sectional studies with
a large range of BMI. There is no correlation between dGEMRIC and BMI in asymptomatic knees, but a negative correlation in OA knees.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Proteoglycans.Introduction
Obesity is a well-known risk factor for osteoarthritis (OA),
the most prevalent joint disease in society1,2. The ability
to measure the relationship between obesity and the molec-
ular structure of cartilage would improve our understanding
of the relationship between obesity and OA. Delayed gado-
linium-enhanced MRI of cartilage (dGEMRIC) may provide
a means to assess the relationship of obesity and cartilage
glycosaminoglycan (GAG) content non-invasively. Several
preliminary studies have previously investigated dGEMRIC
as a means of delineating cartilage molecular quality in
OA3e6.
In the dGEMRIC technique, the negatively charged con-
trast agent Gd-DTPA2 (Magnevist, Berlex, NJ) is injected
intravenously and diffuses into articular cartilage, with a ﬁnal
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Received 23 February 2006; revision accepted 9 May 2006.109concentration inversely proportional to the cartilage GAG
concentration7. The relative GAG concentration is esti-
mated by measuring the T1 values after penetration of the
contrast agent (T1(Gd)). The mean T1(Gd) within a clinically
relevant region of articular cartilage is usually referred to as
the dGEMRIC Index6.
In the current dGEMRIC protocol, Gd-DTPA2 is admin-
istered per kilogram body weight with the assumption that
the distribution volume of the contrast agent is proportional
to body weight. However, because Gd-DTPA2 is distrib-
uted solely in the extracellular water (ECW), and since
lean tissue has approximately twice the ECW content
per unit weight as adipose tissue8, it was recently sug-
gested that different body compositions between individ-
uals might result in a dosing bias with corresponding
bias in the dGEMRIC Index9. Therefore, before studying
the effects of obesity with dGEMRIC, it is important to
evaluate the impact of different body compositions in dos-
ing of the contrast agent.
In the present study we examine (1) plasma Gd-DTPA2-
concentration after an intravenous (IV) injection with dosing
by weight in individuals with a wide range of body mass in-
dices (BMIs), and (2) the correlation between the dGEMRIC
Index and BMI both before and after dose correction in
asymptomatic subjects and subjects with OA.1
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PART 1, PLASMA Gd-DTPA2 CONCENTRATION VS BMI
Twenty-four subjects of varying BMI (Mean 30, range
21e47) were included in the study. BMI was deﬁned as
(body weight, kg)/(height, m)2. The study was approved
by the Institutional Review Board and a written informed
consent was obtained from all subjects. Three milliliters of
blood were drawn pre-contrast and at 15, 30, 45, 60, and
90 min after an IV injection of Gd-DTPA2 at 0.2 mM/kg of
body weight. In 10 subjects (ﬁve obese, ﬁve non-obese,
where obese is deﬁned as BMI 30), blood was obtained
at additional early time-points (3, 5 and 10 min) after the in-
jection in order to compare the plasma time course curves
between obese and non-obese subjects. In ﬁve individuals,
the experiment was repeated for reproducibility at intervals
ranging from 9 to 11 months.
Blood samples were centrifuged, and the plasma sepa-
rated and stored at20(C. For eachmeasurement, samples
were brought to room temperature prior to measurements.
The plasma Gd-DTPA2 concentration was determined
by MR Spectroscopy using an 8.5 T magnet (Bruker Instru-
ments, Billerica, MA). T1 for each plasma sample was
calculated using ParaVision curve ﬁtting software (Bruker
Biospin, Billerica, MA). In 12 of the plasma samples, the Gd-
DTPA2 concentration was also analyzed by high-resolution
inductively coupled plasma atom emission spectrometry
(ICP, Elemental Analysis, Lexington, KY). The correlation
between ICP and MR Spectroscopy measurements for
Gd-DTPA2 concentration was excellent (R2¼ 0.99). All
data reported here are from the MR Spectroscopy.
In some of the ﬁrst subjects investigated, where blood
was drawn from the same arm as the injection, unrealisti-
cally high values of plasma Gd-DTPA2 were found at
15 min post-injection, indicating contamination of Gd-
DTPA2 in the IV catheter. The protocol was therefore
changed after the ﬁrst 12 subjects to drawing blood from
the opposite arm as the IV injection. All of the 10 individuals
whose samples were used for the early time point analysis
had blood drawn from the opposite arm as injection.
PART 2, dGEMRIC vs BMI
dGEMRIC of the knee joint cartilage was performed on
one knee in each of 20 asymptomatic volunteers (BMI
18e43, Mean: 26 6) and in 23 subjects with OA (BMI
22e39, Mean: 28 4). Institutional Review Board approval
was obtained, and all participants gave informed consent.
Subjects with knee OA were recruited from the Mechanical
Factors in Arthritis of the Knee (MAK) study. As previously
described, the MAK subjects had symptomatic knee OA as
deﬁned by the presence of knee pain on most days of the
past month10. dGEMRIC analyses from this cohort were pre-
viously reported relating dGEMRIC to radiographic indices6.
dGEMRIC scans were performed on 1.5 T General Elec-
tric Sigma Excite scanners equipped with TwinSpeed gradi-
ents (GE Healthcare, Waukesha, WI) approximately 90 min
after an IV injection of Gd-DTPA2 at 0.2 mmol/kg body
weight. dGEMRIC was acquired by either 2-D or 3-D
sequence. Singleslicesagittal 2-DdGEMRIC imageswereac-
quired using an Fast spin echo inversion recovery (FSE IR)
sequence with ﬁve inversion delays ranging from 50 to
1680 ms, recovery time/echo time (TR/TE)¼ 1800/14 ms.
Medial and lateral sections from the knee were imaged
sequentially. Three-dimensional images were acquired using
an inversion recovery-prepared fast spoiled gradient-recalledacquisition in the steady state sequence with a 20( ﬂip angle.
Five inversion delays were collected with variable time be-
tween inversion pulses11. Inversion times ranged from 28 ms
to 1650 ms, with a TR ranging from 300 ms to 1950 ms. The
3-D slab was oriented sagittally. In the asymptomatics, 32
slices (3 mm thick) were acquired with 625 625-mm in-plane
resolution; bandwidth (BW) was 42 kHz. In OA patients
imaged as a subset of the MAK study6, 28 slices (3 mm thick)
were acquired with 364 364 mm in-plane resolution;
BW  31.2 kHz.
T1 maps were generated with a pixel-by-pixel three-pa-
rameter ﬁt routine using Matlab (The MathWorks, Natick,
MA). Two sagittal sections from each knee were considered,
one each from the center of the medial and lateral condyles.
In the OA subjects, the femoral compartments were labeled
as ‘‘narrowed’’ or ‘‘unnarrowed’’ based on the joint space
narrowing score on radiographs. The 23 subjects assessed
in this report are a subset of a larger cohort of subjects im-
aged by dGEMRIC and previously reported6. In order to as-
sess inter-subject variation, only the subset of subjects who
had one narrowed and one unnarrowed femoro-tibial com-
partment was considered for this study. dGEMRIC Indices
were calculated in the central weight-bearing femoral carti-
lage (cFC) (the region most prone to early cartilage degener-
ation12,13), and also in the non-weight bearing posterior
femoral cartilage (pFC) and the tibial plateau cartilage
(TP), for a total of three region of interest (ROIs) per section.
In one asymptomatic knee, the dGEMRIC Index could not be
determined from one condyle due to motion artifact thus
yielding a total of 117 dGEMRIC Indices in asymptomatic
volunteers. In nine ROIs from seven OA subjects a valid
dGEMRIC Index could not be determined due to extreme
cartilage thinning. Thus, a total of 129 dGEMRIC Indices
were examined in the OA subjects.
The dGEMRIC Index was calculated both with and with-
out correcting for the dose bias according to the results of
the plasma analysis in Part 1. The correction was done by
calculating the expected difference in plasma Gd-DTPA2
level for each individual based on his/her BMI, relative to
the plasma Gd-DTPA2 level of an individual with BMI 20.
Differences in plasma Gd-DTPA2 levels across people
are referred to as the ‘‘dose bias’’. The T1(Gd) measure-
ment was then corrected to the value it would have if the
plasma Gd-DTPA2 level was reduced by an amount equiv-
alent to the estimated dose bias. BMI correction calcula-
tions are detailed in the Appendix.
STATISTICAL ANALYSIS
Linear regression analysis was used to describe the cor-
relation between BMI and Gd-DTPA2 concentration and
between BMI and the dGEMRIC Index. Friedman repeated
measures analysis of variance (ANOVA) on ranks was used
to compare the Gd-DTPA2 concentration over time in
obese vs non-obese individuals. Coefﬁcient of variation in
percent (C.V.%) was used to describe the intra-individual
variability of repeated analysis of Gd-DTPA2 concentra-
tion. C.V.% was calculated as the standard deviation of
measurement 1measurement 2/ ﬃﬃﬃ2p in percent of the
mean value.
Results
PART 1, PLASMA Gd-DTPA2 CONCENTRATION VS BMI
From the 10 subjects, ﬁve obese and ﬁve non-obese,
investigated with multiple time sampled points, the decay
1093Osteoarthritis and Cartilage Vol. 14, No. 11in plasma Gd-DTPA2 concentration was plotted as a func-
tion of time (Fig. 1). The plasma concentration was higher in
the obese (BMI: 37 6) than in the non-obese (BMI: 26 3)
individuals, P< 0.001. The difference in plasma concentra-
tion between the two groups was between 20% and 25% at
all time-points, indicating a similar plasma elimination rate in
obese and non-obese subjects.
CORRELATION BETWEEN BMI AND Gd-DTPA2
CONCENTRATION
Figure 2 shows the correlation between BMI and plasma
[Gd-DTPA2] from all 24 subjects using the data from blood
sampling 60 min post-injection, R¼ 0.58, P¼ 0.003. The
equation of the regression line is: y¼ 0.0075xþ 0.366. Cal-
culating from this regression line, the plasma [Gd-DTPA2]
of an individual with BMI 45 is 1.36 times higher than the
plasma [Gd-DTPA2] of an individual with BMI 20, 60 min
after the IV injection.
There was a similar positive correlation between BMI and
Gd-DTPA2 concentration at all time-points post-injection of
15, 45, 60, and 90 min with R values ranging from 0.54 to
0.71 (P< 0.05 to P< 0.001). Thus similar ratios (between
1.32 and 1.41) for [Gd-DTPA2] for an individual with BMI
45 to an individual with BMI 20 were found at all post-
injection intervals examined.
REPRODUCIBILITY
In three of the ﬁve subjects whose blood was drawn from
the same arm into which the contrast media were injected,
repeated analyses of plasma Gd-DTPA2 showed unrealis-
tically high Gd-DTPA2 at the 15-min analysis indicating
contamination of Gd-DTPA2 in the catheter. Conse-
quently, the reproducibility in these ﬁve individuals was
low at 15 min with a C.V.% of 52%. However, at 30 min
and beyond, when no contrast medium was residing in
the catheter the reproducibility was very good with
a C.V.% of 1.8%, 2.4%, 3.2% and 3.4% at 30, 45, 60 and
90 min, respectively.
Time (min)
0 20 40 60 80 100 120 140
P
l
a
s
m
a
 
G
d
-
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
M
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Fig. 1. Gadolinium concentration in plasma over time in (closed
diamonds) ﬁve obese (Mean BMI: 37) and (open squares) ﬁve
non-obese (Mean BMI: 26) individuals. The concentration was
higher in the obese subjects (P< 0.001) but the relative difference
between the two groups was similar over time indicating similar
elimination rates. The data agree well with prior data (in red)
reported by Weinmann et al.17.PART 2, dGEMRIC VS BMI
Uncorrected asymptomatic data (Fig. 3) demonstrate
a negative correlation between the dGEMRIC Index and
BMI in both the medial (R¼ 0.574, P¼ 0.01) and lateral
(R¼ 0.464, P¼ 0.04) cFC. There was no correlation be-
tween the dGEMRIC Index and BMI in asymptomatics in ei-
ther the medial or the lateral cFC after correcting for dose
bias. Other compartments (posterior condyle and tibial pla-
teau) showed no signiﬁcant correlation either before or after
dose correction, although both the medial pFC and TP
showed a trend (not signiﬁcant) towards a positive slope
after correction.
Figure 4(a) shows negative correlations between the
dGEMRIC Index and BMI in unnarrowed cFC compart-
ments of subjects with OA both without and with correction
for dose bias (R¼ 0.686, P< 0.001; R¼ 0.571, P¼ 0.004,
respectively). Similar trends were seen in the other regions
of unnarrowed compartments. While a correlation existed
before correction, no correlation between the dGEMRIC In-
dex and BMI was seen in the narrowed compartment after
dose correction [Fig. 4(b)].
Discussion
The positive correlation between Gd-DTPA2 concentra-
tion and BMI after an IV injection with dosing by weight in-
dicates a dosing bias in the present dGEMRIC protocol.
Comparing a subject with BMI 45 (very obese) to another
individual with BMI 20 (lean), the obese person may have
close to 40% higher plasma Gd-DTPA2 concentration after
an IV injection. This dosing bias is presumably due to the
lower ECW fraction in adipose vs lean tissue8. A previous
study directly measured ECW as a function of BMI14. In
that study, non-obese women with an average BMI of
21.2 were found to have 21% ECW relative to the body
weight, whereas obese women with BMI of 46.9 had 16%
ECW. Assuming a linear relationship between %ECW and
Gd-DTPA2 concentration after IV injection, this would
give a higher concentration with a factor of 1.3 in the obese
compared to the non-obese women, and thus the results of
the current study are consistent with the earlier study.
While a correlation existed between plasma Gd-DTPA2
and BMI, there was a fair amount of scatter in the curve.
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Fig. 2. Correlation between BMI and [Gd-DTPA2] at 60 min post-
injection, R ¼ 0.58, P¼ 0.003. The equation of the regression
line, y¼ 0.0075xþ 0.366, is used to calculate dosing bias between
individuals with different BMI.
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Fig. 3. Correlation between the dGEMRIC Index and BMI in asymptomatic subjects before (shaded circles) and after (open circles) dose bias
correction in (a) medial and (b) lateral cFC. The lines represent best-ﬁt linear regression analyses. No signiﬁcant correlation was found after
correction for dose bias.The good reproducibility between repeated plasma spec-
troscopy measurements of the same individuals indicates
that the range of Gd-DTPA2 concentrations that we ob-
serve within a certain BMI-interval (Fig. 2) is due to inter-in-
dividual, and not to intra-individual variability or to
spectroscopic measurement error. The variability between
individuals may relate to different body compositions de-
spite similar BMI. In this regard, BMI is only a predictor of
obesity where, for example, variations in muscle composi-
tion are not taken into account15,16.
The elimination rate of Gd-DTPA2 that we found is con-
sistent with data previously reported by Weinmann et al.17
(Fig. 1). The absolute values of the ﬁve healthy volunteers
who were included in that study were in between those of
the obese and non-obese subjects of the present study, de-
spite that a higher dose was used in the prior study
(0.25 mmol/kg body weight). The BMI of the individuals in
the earlier study was not reported, and may explain the dif-
ference in absolute values of the curves.
Dose bias will be an issue in dGEMRIC where there is
a large range of BMI within a given study and absolutecomparisons are made between individuals. It will also be
an issue in longitudinal studies where patients may follow
a treatment for losing weight and the BMI changes signiﬁ-
cantly over the time course of the study. In these cases,
either dosing by BMI instead of weight can be applied, or
the data need to be post-process corrected. In the extreme
cases of BMI differences, a 40% higher Gd-DTPA2 con-
centration results in approximately 20% lower dGEMRIC
Index (see Appendix for details).
There are a number of situations in which dose bias will
not be a factor. In longitudinal studies where BMI does
not change signiﬁcantly, the dose bias will be present at
all time-points and percent changes with an intervention
will not be affected18. Dose bias will also not be an issue
where different compartments are compared within
a knee6,19. Dose correction may not impact studies not re-
lated to BMI per se; in retrospectively correcting for dose
bias in a recently published study of dGEMRIC compared
with radiography in this same cohort6, none of the conclu-
sions regarding dGEMRIC vs radiographic metrics of OA
were altered.BMI
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Fig. 4. Correlation between the dGEMRIC Index and BMI in OA subjects before (shaded circles) and after (open circles) dose bias correction
in unnarrowed (a) and narrowed (b) compartments. The lines represent best-ﬁt linear regression analyses. There is a strong negative corre-
lation between the dGEMRIC Index and BMI in unnarrowed compartments that persists after correction for dose bias.
1095Osteoarthritis and Cartilage Vol. 14, No. 11There were no signiﬁcant correlations between dGEMRIC
and BMI in asymptomatic subjects. After correcting for dose
bias, there was a trend for a positive correlation in the pos-
terior medial condyle, which might be an indication of upre-
gulated metabolism in healthy joints with increased
mechanical loads. However, this observation could also
be the result of ‘‘over-correcting’’ the dGEMRIC Indices
given some of the assumptions that needed to be incorpo-
rated into the correction scheme (Appendix).
In the unnarrowed compartments of OA subjects, there
was a negative correlation between dGEMRIC and BMI
even after compensating for a dosing bias. The results
are consistent with lower cartilage GAG content with in-
creasing BMI, and may predict progression to more severe
disease in heavier individuals. This has also been the con-
clusion in longitudinal studies of patients with knee OA that
were assessed with conventional radiographs20,21. It can be
speculated that the chondrocytes are unable to maintain
GAG levels under the increased mechanical stress of
increased weight in the diseased joint. In support of this
hypothesis, it was recently shown that overweight is associ-
ated with lower GAG content in patients at high risk of
developing knee OA; in 46 meniscectomized patients, there
was a strong negative correlation between the dGEMRIC
Index and BMI (R¼ 0.5, P< 0.001) approximately 4 years
after the meniscectomy11.
In cases where the joint space is already narrowed, no
correlation between dGEMRIC and BMI was observed in
our study. This may be due to a ‘‘ﬂoor effect’’, as the dGEM-
RIC values in the narrowed compartments were relatively
low across this cohort. This further illustrates that dGEMRIC
may be most valuable in early stages of OA, before joint
space narrowing is present4.
The correction scheme employed several assumptions
that need to be veriﬁed in further studies; in particular the
relaxivity assumed for cartilage in vivo at 1.5 T. However,
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Fig. 5. Bias in T1(Gd) as a result of Gd-DTPA2 dose bias. For
a given GAG level, T1(Gd) should be constant across BMI if
dose bias was not present. The graph shows the variation in
T1(Gd) due to dose bias for [GAG]¼ 0 (shaded circles), 30 (open
circles), 60 (shaded triangles), and 90 (open triangles) mg/ml.
The slopes of the regression lines are nearly the same across
a wide range of GAG levels: m¼2.5, 2.9, 3.1, and 3.2 ms/
BMI, respectively.note that since Fig. 4(a and b) represent data from different
compartments in the same knees, the dose bias could not
account for the different correlations seen with BMI.
In summary, it has been demonstrated that individuals
with higher BMI will receive a higher effective blood plasma
dose of Gd-DTPA2 than individuals with lower BMI. The ef-
fect on the dGEMRIC Index can be important in cases
where cross-sectional comparisons are done with cohorts
exhibiting a range of BMI. In other studies, such as longitu-
dinal evaluation of changes within individuals, the dose
effect will not impact the ﬁndings. The dose bias can be
compensated for by redesigning the dGEMRIC protocol to
dose by BMI, or by post-process correction of the dGEM-
RIC Indices. A negative correlation between dGEMRIC
and BMI was detected in OA knees, but not in asymptom-
atic knees. These ﬁndings deserve further study to better
understand the time course and factors involved in molecu-
lar degeneration of cartilage in degenerative joint disease,
and its association with BMI.
Appendix
The data presented in Fig. 2 of this report demonstrate
a relationship between blood plasma Gd-DTPA2 concen-
tration and BMI, when all individuals are given Gd-DTPA2
doses by weight:
½Gd-DTPA2plasma¼ 0:0075BMIþ 0:366: ð1Þ
The dGEMRIC technique assumes that all individuals
have the same plasma Gd-DTPA2 concentration after in-
jection; therefore, a correction factor needs to be applied
to dGEMRIC data to account for the bias in blood Gd-
DTPA2 levels with BMI.
The following derives the correction that can be made to
calculate the T1(Gd) for an individual to compensate for the
higher plasma Gd-DTPA2 level relative to an individual
with BMI¼ 20 (as a reference BMI).
The T1(Gd) value of cartilage tissue can be calculated
using the standard relaxivity equation and cartilage
parameters:
T1ðGdÞ ¼ 1=ð½Gd-DTPA2tissuer þ ð1=T1oÞÞ ð2Þ
where r¼ relaxivity¼ 4.7 (mmol s)1, and T1o¼ T1 with-
out Gd-DTPA2¼ 1000 ms [Ref. 22]. To our knowledge, the
value of cartilage T1 relaxivity in vivo at 1.5 T in the pres-
ence of Gd-DTPA2 is not known. Here we have estimated
it from previously reported in vitro values and measured
temperature dependence. After equilibration with Gd-
DTPA2, Gillis et al. found T1 relaxivity in bovine cartilage
explants at 2 T to range from 5.18 to 6.28 (mmol s)1 at
room temperature23. The in vitro temperature dependence
measured by Rozijn et al., was found to be 0.087
(mmol s (C)1 [Ref. 24]. To estimate in vivo relaxivity,
we averaged Gillis’ room temperature values and used
Rozijn’s relationship to adjust for a 12(C temperature
increase to body temp (5.73 (mmol s)1þ (0.087 (mmol
 s (C)1) 12(C¼ 4.7(mmol s)1). This estimate is
reasonable given that Gd-DTPA2 T1 relaxivity measured
in whole blood at 37(C at 1.5 T has been reported to range
from 4.0 to 4.6 (mmol s)1 [Ref. 25]. Since relaxivity in-
creases with macromolecular content, its value in cartilage
tissue can be expected to be somewhat higher than that in
blood.
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plasma by rear-
ranging the equation for the distribution of a charged ion
in a charged matrix7:
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Here the FCD is the ﬁxed charge density of the cartilage, re-
lated to GAG concentration by:
FCD; mM¼ ð2 charges=GAGÞ
ð½GAG; mg=mlÞ=ð0:5025 mg=molÞ: ð4Þ
For a constant GAG concentration, the Gd-DTPA2tissue,
and hence T1(Gd), should be constant across individuals
if their Gd-DTPA2plasma levels are constant. The variation
of T1(Gd) due to varying Gd-DTPA2plasma concentration
with BMI can be approximated by combining the relation-
ship between BMI and Gd-DTPA2plasma (Eq. 1) with the
relationships between [GAG], Gd-DTPA2plasma, and Gd-
DTPA2tissue (Eqs. 3 and 4) and the relationship between
Gd-DTPA2tissue and T1(Gd) (Eq. 2). The result is an estimate
of T1(Gd) as a function of BMI for a given GAG concentra-
tion. This function is plotted in Fig. 5 for different GAG
levels. The slopes of the regression lines are nearly the
same across a wide range of GAG levels (m¼2.5,
2.9, 3.1, and 3.2 ms/BMI, for [GAG]¼ 0, 30, 60, and
90 mg/ml, respectively); therefore we can write the ‘‘cor-
rected’’ T1 to that of an individual with BMI¼ 20 as:
T1ðcorrectedÞ ¼ T1ðmeasuredÞ þ 3ðBMI 20Þ ð5Þ
where the slope was corrected for T1 values given in ms.
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